SI3512495T1 - Formulacije prostaciklinskih analogov - Google Patents
Formulacije prostaciklinskih analogovInfo
- Publication number
- SI3512495T1 SI3512495T1 SI201731280T SI201731280T SI3512495T1 SI 3512495 T1 SI3512495 T1 SI 3512495T1 SI 201731280 T SI201731280 T SI 201731280T SI 201731280 T SI201731280 T SI 201731280T SI 3512495 T1 SI3512495 T1 SI 3512495T1
- Authority
- SI
- Slovenia
- Prior art keywords
- formulations
- prostacyclin analogues
- prostacyclin
- analogues
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1615754.7A GB201615754D0 (en) | 2016-09-15 | 2016-09-15 | Formulations |
| GBGB1621277.1A GB201621277D0 (en) | 2016-12-14 | 2016-12-14 | Formulations |
| PCT/EP2017/073359 WO2018050864A1 (en) | 2016-09-15 | 2017-09-15 | Prostacyclin analogue formulations |
| EP17768124.4A EP3512495B1 (en) | 2016-09-15 | 2017-09-15 | Prostacyclin analogue formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3512495T1 true SI3512495T1 (sl) | 2023-01-31 |
Family
ID=59887281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201731280T SI3512495T1 (sl) | 2016-09-15 | 2017-09-15 | Formulacije prostaciklinskih analogov |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11369617B2 (enExample) |
| EP (1) | EP3512495B1 (enExample) |
| JP (1) | JP7527785B2 (enExample) |
| KR (1) | KR20190083645A (enExample) |
| CN (1) | CN109715138B (enExample) |
| AU (1) | AU2017328630B2 (enExample) |
| CA (1) | CA3036307A1 (enExample) |
| DK (1) | DK3512495T3 (enExample) |
| ES (1) | ES2933175T3 (enExample) |
| IL (1) | IL265270B (enExample) |
| LT (1) | LT3512495T (enExample) |
| MX (1) | MX390136B (enExample) |
| PL (1) | PL3512495T3 (enExample) |
| PT (1) | PT3512495T (enExample) |
| RU (1) | RU2757903C2 (enExample) |
| SI (1) | SI3512495T1 (enExample) |
| WO (1) | WO2018050864A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109150387B (zh) | 2017-06-16 | 2023-04-28 | 华为技术有限公司 | 发送参考信号的方法、接收参考信号的方法和通信装置 |
| WO2020240018A1 (en) | 2019-05-29 | 2020-12-03 | Camurus Ab | Administration device & regime |
| KR102628523B1 (ko) * | 2020-06-30 | 2024-01-24 | 주식회사 종근당 | GnRH 유도체를 포함하는 주사용 조성물 |
| MX2023003506A (es) * | 2020-09-25 | 2023-06-28 | Algorithm Sciences Inc | Composiciones y métodos para la administración de vasodilatadores. |
| WO2024107096A1 (en) * | 2022-11-14 | 2024-05-23 | Camurus Ab | Treprostinil formulations |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4125255A1 (de) | 1991-07-31 | 1993-02-04 | Knoll Ag | Prostaglandin e (pfeil abwaerts)1(pfeil abwaerts)-formulierung |
| DK0711148T3 (da) | 1993-07-28 | 2001-01-02 | Pharmaderm Lab Ltd | Dobbeltfasede multilamellære lipidblærer |
| SE0201659D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Modified release pharmaceutical formulation |
| CN102697790A (zh) * | 2003-05-22 | 2012-10-03 | 联合治疗公司 | 化合物和释放前列环素类似物的方法 |
| PL1768650T3 (pl) | 2004-06-04 | 2009-01-30 | Camurus Ab | Ciekłe formulacje depot |
| GB0412530D0 (en) * | 2004-06-04 | 2004-07-07 | Camurus Ab | Formulation |
| CA2574958A1 (en) * | 2004-07-26 | 2006-02-09 | Cotherix, Inc. | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
| PL1848403T3 (pl) | 2005-01-14 | 2010-09-30 | Camurus Ab | Preparaty bioadhezyjne o działaniu miejscowym |
| PL1845942T3 (pl) | 2005-01-14 | 2014-07-31 | Camurus Ab | Preparaty analogu GnRH |
| PL1888031T3 (pl) | 2005-06-06 | 2013-04-30 | Camurus Ab | Preparaty analogu glp-1 |
| BR112013030104A8 (pt) | 2011-05-25 | 2021-09-08 | Camurus Ab | Pré-formulação, processo para a formação de uma pré-formulação, método de tratamento cosmético, dispositivo de administração preenchido, e, kit |
| BR112014003225A2 (pt) | 2011-08-12 | 2017-03-01 | Ascendis Pharma As | profármacos de treprostinil ligados a veículo |
| AU2012296953B2 (en) * | 2011-08-12 | 2016-10-20 | Ascendis Pharma A/S | Sustained release composition of prostacyclin |
| WO2013038460A1 (ja) | 2011-09-16 | 2013-03-21 | 株式会社日立製作所 | 画像表示システム及びその方法 |
| US9555118B2 (en) | 2011-12-05 | 2017-01-31 | Camrus Ab | Robust controlled-release peptide formulations |
| AU2013294915C1 (en) * | 2012-07-26 | 2019-11-21 | Camurus Ab | Opioid formulations |
| WO2014085813A1 (en) * | 2012-11-30 | 2014-06-05 | Insmed Incorporated | Prostacylin compositions and methods for using the same |
| KR101586790B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| WO2015138423A1 (en) | 2014-03-11 | 2015-09-17 | Insmed Incorporated | Prostacylin compositions and methods for using the same |
| GB201419091D0 (en) | 2014-10-27 | 2014-12-10 | Camurus Ab | Formulations |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
-
2017
- 2017-09-15 JP JP2019514208A patent/JP7527785B2/ja active Active
- 2017-09-15 SI SI201731280T patent/SI3512495T1/sl unknown
- 2017-09-15 PL PL17768124.4T patent/PL3512495T3/pl unknown
- 2017-09-15 DK DK17768124.4T patent/DK3512495T3/da active
- 2017-09-15 IL IL265270A patent/IL265270B/en unknown
- 2017-09-15 CA CA3036307A patent/CA3036307A1/en active Pending
- 2017-09-15 LT LTEPPCT/EP2017/073359T patent/LT3512495T/lt unknown
- 2017-09-15 AU AU2017328630A patent/AU2017328630B2/en active Active
- 2017-09-15 WO PCT/EP2017/073359 patent/WO2018050864A1/en not_active Ceased
- 2017-09-15 PT PT177681244T patent/PT3512495T/pt unknown
- 2017-09-15 CN CN201780056712.7A patent/CN109715138B/zh active Active
- 2017-09-15 ES ES17768124T patent/ES2933175T3/es active Active
- 2017-09-15 MX MX2019002999A patent/MX390136B/es unknown
- 2017-09-15 US US16/333,448 patent/US11369617B2/en active Active
- 2017-09-15 EP EP17768124.4A patent/EP3512495B1/en active Active
- 2017-09-15 KR KR1020197008219A patent/KR20190083645A/ko not_active Ceased
- 2017-09-15 RU RU2019108832A patent/RU2757903C2/ru active
-
2022
- 2022-06-09 US US17/836,120 patent/US20220387445A1/en not_active Abandoned
-
2024
- 2024-11-12 US US18/945,113 patent/US20250319097A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3512495B1 (en) | 2022-11-09 |
| CA3036307A1 (en) | 2018-03-22 |
| PT3512495T (pt) | 2023-02-15 |
| IL265270B (en) | 2022-09-01 |
| US20190255068A1 (en) | 2019-08-22 |
| RU2757903C2 (ru) | 2021-10-22 |
| US20220387445A1 (en) | 2022-12-08 |
| CN109715138A (zh) | 2019-05-03 |
| MX390136B (es) | 2025-03-20 |
| KR20190083645A (ko) | 2019-07-12 |
| CN109715138B (zh) | 2022-06-28 |
| AU2017328630B2 (en) | 2020-06-18 |
| RU2019108832A (ru) | 2020-10-15 |
| MX2019002999A (es) | 2019-07-18 |
| IL265270A (en) | 2019-05-30 |
| RU2019108832A3 (enExample) | 2020-11-30 |
| PL3512495T3 (pl) | 2023-01-23 |
| JP7527785B2 (ja) | 2024-08-05 |
| DK3512495T3 (da) | 2022-12-05 |
| US20250319097A1 (en) | 2025-10-16 |
| AU2017328630A1 (en) | 2019-04-11 |
| ES2933175T3 (es) | 2023-02-02 |
| US11369617B2 (en) | 2022-06-28 |
| EP3512495A1 (en) | 2019-07-24 |
| WO2018050864A1 (en) | 2018-03-22 |
| LT3512495T (lt) | 2022-12-27 |
| JP2019529408A (ja) | 2019-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268697A (en) | Formulations | |
| DK3688162T3 (da) | Formuleringer | |
| MA46180A (fr) | Analogues de l'amyline | |
| EP3509581A4 (en) | FORMULATIONS OF (R | |
| SI3769781T1 (sl) | Stabilna formulacija proti-IFNAR1 | |
| IL272851A (en) | Methods of using dipivefrin | |
| PT3645518T (pt) | Síntese de omecamtiv mecarbil | |
| EP3364956A4 (en) | ANALOG OF CELASTROL | |
| EP3406336A4 (en) | NANO FOIL OF CORE CASE STRUCTURE TYPE | |
| PL3457851T3 (pl) | Pochodne sobetiromu | |
| EP3710462A4 (en) | BRARTEMICIN ANALOGA | |
| EP3347334A4 (en) | DEHYDROHALOGENICATION OF FLUOROCHOLE HYDROGEN | |
| DK3474822T3 (da) | Formuleringer af brincidofovir | |
| IL248223A0 (en) | Vaccine compositions | |
| EP3600279A4 (en) | 1-amino-1-cyclopropanecaboxylic acid formulations | |
| PT3206672T (pt) | Formulações de libertação prolongada de anestésicos locais | |
| IL272857A (en) | Cofanalisib formulations | |
| EP3277701A4 (en) | SYNTHESIS OF DESOSAMINES | |
| IL254502B (en) | Solid forms of menaquinols | |
| EP3407974A4 (en) | Amlexanox Analogs | |
| DK3512495T3 (da) | Formuleringer af prostacyklinanaloger | |
| IL258630B1 (en) | Formulation of l-ornithine phenylacetate | |
| IL272167A (en) | Hemopexin formulations | |
| EP3473373A4 (en) | solder compositions | |
| LT3652187T (lt) | Patobulintas imetelstato gamybos būdas |